MoFo advised ai3Bio, a biotechnology company developing therapies designed to address autoimmune disease at its source, in connection with its $48 million Series A financing. The financing was led by UPMC Enterprises and Ziff Capital Partners, with participation from Cockrell Interests and Tanis Ventures.
The financing will support advancement of its STARx and T Deplete platforms, including investigational new drug (IND) enabling studies toward first-in-human trials. The company is pursuing a novel approach to autoimmune disease treatment by selectively targeting and eliminating disease-causing Th17 cells rather than broadly suppressing the immune system. Its two complementary platforms use lipid nanoparticle-delivered mRNA and antibody-based technology, respectively.
The MoFo team advising ai3Bio included corporate partner Jim Krenn, of counsels Andrew Dixon and Anthony Krueger, employment and labor partner Michael Schulman, tax partner Shane Shelley, executive compensation and benefits partner Josh Lerner, technology transactions partners Matt Ferry and Kathleen Kean, patent partner Meghan Poon, senior of counsel Catherine Polizzi and senior patent agent Christine Lekutis, and regulatory partner Brigid Bondoc.
Jim Krenn
Chair of Emerging Companies + Venture Capital Practice